Navigation Links
Tobira Therapeutics Inc. Announces Phase I Pharmacokinetic Data of TBR-652 for the Treatment of HIV

PRINCETON, N.J. and SAN DIEGO, Sept. 14 /PRNewswire/ -- Tobira Therapeutics Inc., a clinical stage biotechnology company committed to research and product discovery for the treatment of life-threatening and life-altering infectious diseases, today announced pharmacokinetic data and results from a double-blind, placebo-controlled, multiple-dose randomized study of TBR-652 in sixty healthy volunteers. TBR-652, a CCR5 antagonist under investigation for the treatment of HIV, was evaluated at doses ranging from 25 mg once daily (QD) to 200 mg QD after a high fat meal. Pharmacokinetic parameters were measured on Days 1 and 10, while safety and tolerability were evaluated throughout the 10 day study. The results of the study demonstrate TBR-652 was well tolerated in all groups. TBR-652 reached maximum plasma exposure 3-6 hours post dose on Days 1 and 10. Mean plasma half-life ranged from 40 to 45 hours, supporting once daily dosing. Exposure pharmacokinetic measures were greater than the therapeutic level projected from in vitro studies of TBR-652.

"This Phase I study provides further clinical support for the continued development of TBR-652 in the treatment of HIV. We are very encouraged by the excellent exposure results from the study and look forward to results from ongoing trials," said James Sapirstein, CEO.

These data were presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), held September 12-15, 2009 in San Francisco, California. The poster presentation can be viewed at

About Tobira Therapeutics Inc.

Tobira Therapeutics is a private biopharmaceutical company which is focused on developing and commercializing innovative antiviral compounds to treat HIV disease. The company was founded in 2006 by Eckard Weber, MD, a partner at the venture capital firm Domain Associates, to develop novel treatments for HIV disease. Tobira has assembled a highly experienced management team with decades of clinical and commercial development experience specifically in HIV/AIDS drug development.

    Tobira Therapeutics Inc.
    Antoinette Bobbitt Tobira Therapeutics Inc.
    Tel: 609-897-1102

SOURCE Tobira Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Tobira Therapeutics Inc. Announces Phase I Data Demonstrating Pharmacokinetic Properties of TAK-652 for the Treatment of HIV
2. Tobira Therapeutics Inc. Announces Key Addition to Scientific Advisory Board
3. Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum
4. Tobira Therapeutics Inc. Announces Senior Management Team
5. Elkan Gamzu, Ph.D. Joins Hygeia Therapeutics Board of Directors as Chair
6. Precision Therapeutics Named to Inc. Magazines List of Fastest Growing Companies
7. PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis
8. /C O R R E C T I O N -- Clinical Therapeutics/
9. Cell Therapeutics, Inc. (CTI) to Present at BioCenturys NewsMakers in the Biotech Industry Conference
10. Oxygen Biotherapeutics, Inc. Seeks Shareholder Approval for Reverse Stock Split
11. Orexigen(R) Therapeutics to Speak at Upcoming Conferences
Post Your Comments:
(Date:11/25/2015)... -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today ... Neurocrine Biosciences, will be presenting at the 27th Annual ... . .   Listeners ... prior to the presentation to download or install any ... available on the website approximately one hour after the ...
(Date:11/25/2015)... -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX ) today ... discussion at the Piper Jaffray 27th Annual Healthcare Conference ... is scheduled for Wednesday, December 2, at 8:00 a.m. ... will be available for 14 days after the event.  ... Corporate Communications and Business Development , BrewLife(858) 875-8629 ...
(Date:11/24/2015)... 2015  Asia-Pacific (APAC) holds the third-largest share ... The trend of outsourcing to low-cost locations is ... volume share for the region in the short ... in the CRO industry will improve. ... ), finds that the market earned revenues ...
(Date:11/24/2015)... SAN DIEGO , Nov. 24, 2015 Halozyme Therapeutics, ... Jaffray Healthcare Conference in New York on ... Dr. Helen Torley , president and CEO, will provide a ... New York at 1:00 p.m. ET/10:00 a.m. ... communication and investor relations, will provide a corporate overview. --> ...
Breaking Biology Technology:
(Date:11/9/2015)... ) ... "Global Law Enforcement Biometrics Market 2015-2019" ... ) has announced the addition of ... 2015-2019" report to their offering. ... ) has announced the addition of the ...
(Date:11/2/2015)... Calif. , Nov. 2, 2015  SRI International ... million to provide preclinical development services to the National ... contract, SRI will provide scientific expertise, modern testing and ... variety of preclinical pharmacology and toxicology studies to evaluate ... --> The PREVENT Cancer Drug Development Program ...
(Date:10/29/2015)... , Oct. 29, 2015 Daon, a ... that it has released a new version of its ... in North America have already ... v4.0 also includes a FIDO UAF certified server ... already preparing to activate FIDO features. These customers include ...
Breaking Biology News(10 mins):